[
  {
    "ts": null,
    "headline": "Biotech: 3 Reasons The Recent Selloff Is A Buying Opportunity For XBI (Upgrade)",
    "summary": "SPDRÂ® S&P Biotech ETF had its worst week since 2020, but the sector remains undervalued. Read why XBI is a strong buy for patient investors.",
    "url": "https://finnhub.io/api/news?id=109ddd120641122e255332ba00679b7b978c2e03ced531275de667fe4d7d4cd2",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1732021874,
      "headline": "Biotech: 3 Reasons The Recent Selloff Is A Buying Opportunity For XBI (Upgrade)",
      "id": 131480822,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/155151969/image_155151969.jpg?io=getty-c-w1536",
      "related": "MRNA",
      "source": "SeekingAlpha",
      "summary": "SPDRÂ® S&P Biotech ETF had its worst week since 2020, but the sector remains undervalued. Read why XBI is a strong buy for patient investors.",
      "url": "https://finnhub.io/api/news?id=109ddd120641122e255332ba00679b7b978c2e03ced531275de667fe4d7d4cd2"
    }
  },
  {
    "ts": null,
    "headline": "BioNTech Stock Has Been Hit Hard Since RFK Jr.’s Nomination. Why This Analyst Upgraded It.",
    "summary": "BioNTech Stock Has Been Hit Hard Since RFK Jr.’s Nomination. Why This Analyst Upgraded It.",
    "url": "https://finnhub.io/api/news?id=86f1072bb8ddf5880fad8de189b79a3d5ef21744dc3348ce38e64d7ac8e4a46e",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1732017420,
      "headline": "BioNTech Stock Has Been Hit Hard Since RFK Jr.’s Nomination. Why This Analyst Upgraded It.",
      "id": 131508366,
      "image": "",
      "related": "MRNA",
      "source": "MarketWatch",
      "summary": "BioNTech Stock Has Been Hit Hard Since RFK Jr.’s Nomination. Why This Analyst Upgraded It.",
      "url": "https://finnhub.io/api/news?id=86f1072bb8ddf5880fad8de189b79a3d5ef21744dc3348ce38e64d7ac8e4a46e"
    }
  },
  {
    "ts": null,
    "headline": "HSBC upgrades Moderna to Buy on pipeline potential",
    "summary": "HSBC analyst Yifeng Liu upgraded Moderna (MRNA) to Buy from Hold with a price target of $58, down from $82. The recent share price weakness reflects worries over the company’s path back to growth story, the analyst tells investors in a research note. The firm says that if Moderna’s existing key pipeline products manage to launch successfully and RSV-vaccine recommendation pressure eases, there could be attractive upside potential for the stock. Published first on TheFly – the ultimate source for",
    "url": "https://finnhub.io/api/news?id=1d94d4c998a85f3268845b6a47a7e8da8e1fbbcafe4b3f605cac2e307926969b",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1732015805,
      "headline": "HSBC upgrades Moderna to Buy on pipeline potential",
      "id": 131471349,
      "image": "https://media.zenfs.com/en/tipranks_452/77a747ee2b92f942aa044f4f47d9af54",
      "related": "MRNA",
      "source": "Yahoo",
      "summary": "HSBC analyst Yifeng Liu upgraded Moderna (MRNA) to Buy from Hold with a price target of $58, down from $82. The recent share price weakness reflects worries over the company’s path back to growth story, the analyst tells investors in a research note. The firm says that if Moderna’s existing key pipeline products manage to launch successfully and RSV-vaccine recommendation pressure eases, there could be attractive upside potential for the stock. Published first on TheFly – the ultimate source for",
      "url": "https://finnhub.io/api/news?id=1d94d4c998a85f3268845b6a47a7e8da8e1fbbcafe4b3f605cac2e307926969b"
    }
  }
]